Kunio Yui

List of Publications by Year
in descending order

46 papers	980 citations	430874 18 h-index	434195 31 g-index
48 all docs	48 docs citations	48 times ranked	1340 citing authors

#	Article	IF	Citations
1	Urinary and Plasma Antioxidants in Behavioral Symptoms of Individuals With Autism Spectrum Disorder. Frontiers in Psychiatry, 2021, 12, 684445.	2.6	4
2	Lipid Peroxidation With Implication of Organic Pollution in Autistic Behaviors. Cureus, 2021, 13, e14188.	0.5	0
3	The role of lipid peroxidation in individuals with autism spectrum disorders. Metabolic Brain Disease, 2020, 35, 1101-1108.	2.9	7
4	Contribution of Transferrin and Ceruloplasmin Neurotransmission and Oxidant/Antioxidant Status to the Effects of Everolimus: A Case Series. Cureus, 2020, 12, e6920.	0.5	2
5	Improvement in Impaired Social Cognition but Not Seizures by Everolimus in a Child with Tuberous Sclerosis-Associated Autism through Increased Serum Antioxidant Proteins and Oxidant/Antioxidant Status. Case Reports in Pediatrics, 2019, 2019, 1-10.	0.4	7
6	Decreased total antioxidant capacity has a larger effect size than increased oxidant levels in urine in individuals with autism spectrum disorder. Environmental Science and Pollution Research, 2017, 24, 9635-9644.	5.3	17
7	Reduced endogenous urinary total antioxidant power and its relation of plasma antioxidant activity of superoxide dismutase in individuals with autism spectrum disorder. International Journal of Developmental Neuroscience, 2017, 60, 70-77.	1.6	12
8	Therapeutic Potential of Everolimus on Core Autism Symptoms and Increasing Serum Ceruloplasmin and Transferrin Levels in a Pubescent Boy with Tuberous Sclerosis. Neonatal and Pediatric Medicine, 2017, 03, .	0.1	1
9	Editorial (Thematic Issue: New Therapeutic Targets for Autism Spectrum Disorders). CNS and Neurological Disorders - Drug Targets, 2016, 15, 529-532.	1.4	2
10	Increased Ï‰-3 polyunsaturated fatty acid/arachidonic acid ratios and upregulation of signaling mediator in individuals with autism spectrum disorders. Life Sciences, 2016, 145, 205-212.	4.3	29
11	Down-regulation of a signaling mediator in association with lowered plasma arachidonic acid levels in individuals with autism spectrum disorders. Neuroscience Letters, 2016, 610, 223-228.	2.1	17
12	Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator. Medicinal Chemistry, 2016, 12, 318-327.	1.5	3
13	Psycho-Cognitive Intervention for ASD from Cross-Species Behavioral Analyses of Infants, Chicks and Common Marmosets. CNS and Neurological Disorders - Drug Targets, 2016, 15, 578-586.	1.4	6
14	Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders. CNS and Neurological Disorders - Drug Targets, 2016, 15, 587-596.	1.4	57
15	EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders). Current Neuropharmacology, 2015, 13, 736-738.	2.9	0
16	Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 353-354.	2.4	0
17	Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders. Mini-Reviews in Medicinal Chemistry, 2015, 15, 373-389.	2.4	32
18	Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. Current Neuropharmacology, 2015, 13, 776-785.	2.9	74

#	Article	IF	Citations
19	A cross-species socio-emotional behaviour development revealed by a multivariate analysis. Scientific Reports, 2013, 3, 2630.	3.3	11
20	Effects of Large Doses of Arachidonic Acid Added to Docosahexaenoic Acid on Social Impairment in Individuals With Autism Spectrum Disorders. Journal of Clinical Psychopharmacology, 2012, 32, 200-206.	1.4	88
21	Effects of constant daylight exposure during early development on marmoset psychosocial behavior. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1493-1498.	4.8	17
22	Comparison of Behavioural Effects of Repeated Treatment with Methamphetamine plus Scopolamine and Methamphetamine Alone on Behavioural Sensitization and Conditioned Response. Journal of Pharmacy and Pharmacology, 2011, 47, 852-856.	2.4	1
23	Oseltamivir (TamifluÂ®) increases dopamine levels in the rat medial prefrontal cortex. Neuroscience Letters, 2008, 438, 67-69.	2.1	41
24	Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. NeuroToxicology, 2008, 29, 1030-1036.	3.0	49
25	Neurobiological and Molecular Bases of Methamphetamine-Induced Behavioral Sensitization and Spontaneous Recurrence of Methamphetamine Psychosis, and its Implication in Schizophrenia. Current Psychiatry Reviews, 2006, 2, 381-393.	0.9	0
26	The Role of Noradrenergic and Dopaminergic Hyperactivity in the Development of Spontaneous Recurrence of Methamphetamine Psychosis and Susceptibility to Episode Recurrence. Annals of the New York Academy of Sciences, 2004, 1025, 296-306.	3.8	21
27	Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neuroscience Letters, 2004, 364, 16-21.	2.1	28
28	Susceptibility to Episode Recurrence in Spontaneous Recurrence of Methamphetamine Psychosis. Journal of Clinical Psychopharmacology, 2003, 23, 525-528.	1.4	6
29	Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT1A receptors in the rat medial frontal cortex. Neurochemistry International, 2002, 40, 355-360.	3.8	51
30	Factors for Susceptibility to Episode Recurrence in Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 2002, 965, 292-304.	3.8	21
31	Susceptibility to subsequent episodes of spontaneous recurrence of methamphetamine psychosis1Institute at which the work was carried out: Department of Legal Medicine and Human Genetics, Jichi Medical School, Minamikawachi, Tochigi 329-0498, Japan, and Medical Care Section, Tochigi Prison, Ministry of Justice, Sozya 2484, Tochigi 328-0002, Japan.1. Drug and Alcohol Dependence, 2001, 64, 133-143.	3.2	25
32	Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Research, 2001, 890, 23-31.	2.2	143
33	Preface: Recent advances of neurobiological basis of stimulant-induced sensitization. Addiction Biology, 2000, 5, 321-324.	2.6	0
34	Increased sensitivity to stress associated with noradrenergic hyperactivity, involving dopaminergic hyperactivity in spontaneous recurrences in methamphetamine psychosis. Addiction Biology, 2000, 5, 343-350.	2.6	2
35	Studies of Amphetamine or Methamphetamine Psychosis in Japan: Relation of Methamphetamine Psychosis to Schizophrenia. Annals of the New York Academy of Sciences, 2000, 914, 1-12.	3.8	82
36	Susceptibility to Subsequent Episodes in Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 2000, 914, 292-302.	3.8	19

#	Article	IF	Citations
37	Stress induced spontaneous recurrence of methamphetamine psychosis: the relation between stressful experiences and sensitivity to stress. Drug and Alcohol Dependence, 2000, 58, 67-75.	3.2	25
38	Increased Sensitivity to Stress in Spontaneous Recurrence of Methamphetamine Psychosis: Noradrenergic Hyperactivity With Contribution From Dopaminergic Hyperactivity. Journal of Clinical Psychopharmacology, 2000, 20, 165-174.	1.4	20
39	Monoamine Metabolites Analysis in Blood and the Relation to Flashback Occurrence in Methamphetamine Psychosis. Japanese Journal of Science and Technology for Identification, 1998, 3, 37-48.	0.2	0
40	Monoamine Neurotransmitter Metabolites and Spontaneous Recurrence of Methamphetamine Psychosis. Brain Research Bulletin, 1997, 43, 25-33.	3.0	4
41	Methamphetamine Psychosis. Journal of Clinical Psychopharmacology, 1997, 17, 34-43.	1.4	29
42	Monoamine Neurotransmitter Function and Spontaneous Recurrence of Methamphetamine Psychosis. Annals of the New York Academy of Sciences, 1996, 801, 415-429.	3.8	5
43	Plasma monoamine metabolites and spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory psychosis: relation of noradrenergic activity to the occurrence of flashbacks. Psychiatry Research, 1996, 63, 93-107.	3.3	7
44	Effects of repeated treatment with methamphetamine plus scopolamine and methamphetamine on behavioral sensitization and conditioning. Behavioural Brain Research, 1996, 80, 169-175.	2.2	5
45	Behavioral Responses Induced by Repeated Treatment with Methamphetamine Alone and in Combination with Scopolamine in Rats. Neuropsychobiology, 1996, 33, 21-27.	1.9	4
46	Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning. European Journal of Pharmacology, 1995, 279, 135-142.	3.5	6